Press Conference Update: Companies to Display Visible Progress in Meeting Advanced Biofuels Goals

Biotechnology Industry Organization:

A teleconference line has been established for reporters unable to attend in person. Dial-in: 800-277-3988.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO India International Conference September 12 13, 2012 Mumbai, India

Livestock Biotech Summit September 19 21, 2012 Kansas City, MO

BIO Investor Forum October 9-10, 2012 San Francisco, CA

Pacific Rim Summit on Industrial Biotechnology and Bioenergy October 10 12, 2012 Vancouver, Canada

The BIO Convention in China October 24 25, 2012 Shanghai, China

Read the original here:
Press Conference Update: Companies to Display Visible Progress in Meeting Advanced Biofuels Goals

Research and Markets: Animal Biotechnology – Technologies, Markets and Companies – Updated 2012 Report

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cgq6bx/animal_biotechnolo) has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals. There is discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans. RNA interference technology is now being applied for research in veterinary medicine

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 109 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 109 collaborations in this area are shown.

Share of biotechnology-based products and services in 2011 is analyzed and the market is projected to 2021.

The text is supplemented with 34 tables and 5 figures. Selected 250 references from the literature are appended.

See the article here:
Research and Markets: Animal Biotechnology - Technologies, Markets and Companies - Updated 2012 Report

Bharathidasan Varsity announces M.Phil in industrial biotechnology

Department of Industrial Biotechnology, Bharathidasan University, has announced an M.Phil programme.

Factoring in the rapidly evolving scenario in industrial biotechnology in the areas of regulatory infrastructure, improving standards of bio-manufacturing, increasing capabilities in food technology and development, increasing research and development collaborations with Indian and international companies, the Department of Industrial Biotechnology, Bharathidasan University, has announced an M.Phil programme in the subject from 2012-13.

The innovative course, according to professor and department head T.Thirunalasundari, will fill the gap between expectations of biotechnology industry and skills created by higher education sector, combining research, entrepreneurial skills and industrial placement experience in biotechnology companies all over the world.

Application of biotechnology in the production of industrial materials is expected to transform industrial manufacturing sector similar to the impact created by pharmaceutical and agricultural sectors.

Sustainable development in the general industrial sector implies applying know how and technologies to reduce material and energy consumption, increase use of renewable and biodegradable materials, generate less pollution and waste, and produce more environmental friendly products.

Technical application of industrial biotechnology holds promise for arriving at new tools, techniques and know how for the sustainable development. Some of the new applications include gene therapy, drug designing, tissue engineering and regenerative medicines, cloning, pharma products and agriculture, Dr.Thirunalasundari explained. The curriculum has been designed by distinguished scientists and academicians, industrial experts and technologists.

The department, she said, has tie ups with research institutions and commercial industries. The programme will not only lead to assured placement in industries and create scope for pursuing higher education in India and abroad, but also enable candidates to transform into entrepreneurs if they desire.

Candidates of M.Sc. Biotechnology, Biochemistry, Microbiology, Botany, Zoology and other related life science disciplines are considered eligible for the M.Phil programme of one-year duration.

Applications can be downloaded from the university website http://www.bdu.ac.in and submitted before September 14.

For more details, dial 0431 2407066 (559) or email headbt@bdu.ac.in.

Excerpt from:
Bharathidasan Varsity announces M.Phil in industrial biotechnology

New facilities for biotechnology study at Vellayani College of Agriculture

The new blocks will aid further learning and experimentation for students pursing M.Sc. (Integrated) Biotechnology course at the college

Chief Minister Oommen Chandy will inaugurate the newly built integrated biotechnology block and the microbial technology block at the College of Agriculture, Vellayani, on Monday.

Apart from opening the Centre for Microbial Technology and Microbial Inoculants Production Unit, Mr. Chandy will also release the National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation certificate for the pesticide residue analytical laboratory at a function on the college campus. Minister for Agriculture K.P. Mohanan will preside over the function.

The new blocks will aid further learning and experimentation for students pursing M.Sc. (Integrated) Biotechnology course at the college. The five-year course was started in the college in 2009 as per the directions of the State government with the aim of improving the quality of biotechnology education. The course had started with 20 students in a batch and an amount of Rs.1.90 crore was provided as a one-time grant for the initiation of the course. The course is offered and coordinated by Kerala Agricultural University using a core facility with the active involvement of five institutions dealing with biotechnology, according to a press release.

Read more:
New facilities for biotechnology study at Vellayani College of Agriculture

Biotechnology has potential to be medium for Sabah’s growth

Posted on August 31, 2012, Friday

KOTA KINABALU: Biotechnology has the potential to become the medium for economic growth and generate new wealth for the state as well as increase the rakyats income, says Sabah Chief Minister Datuk Seri Musa Aman.

In this regard, he said the state government, through its Halatuju development agenda, has outlined the needs for the benefits of science and technology, especially biotechnology for development.

Towards this end, several initiatives have taken off to facilitate the rakyats participation in biotechnology focusing on knowledge, he said in his speech at a briefing on Bioeconomy in Sabah Development Corridor (SDC), here yesterday. Also present was Minister of Science, Technology and Innovation Datuk Seri Dr Maximus Ongkili.

Musa, who was also state finance minister, said the initiatives included implementing various key projects such as Sabah Agro-Industrial Precinct (SAIP), Palm Oil Industrial Cluster (POIC) and Keningau Integrated Livestock Farming Centre.

Research on biomass policy, non-wood forest products and marine resources was also carried out to strengthen the states bioeconomy development, he said.

Musa said such efforts showed the commitment, determination and earnestness of the government via the Economic Transformation Programme, which was the catalyst for Sabahs economic progress.

I believe this will be able to create more job opportunities and change the economic scenario of the state, he said.

He said the implementation of SDCs phase two investment spearheaded by the private sector also played an active role including in bioeconomy development.

Musa was also confident that Sabah has a huge potential in attracting biotechnology industry to the state and subsequently increase the states economy to a higher level.

More:
Biotechnology has potential to be medium for Sabah’s growth

One-pot bioethanol production from cellulose by co-culture of Acremonium cellulolyticus and Saccharomyces cerevisiae

Background:
While the ethanol production from biomass by consolidated bioprocess (CBP) is considered to be the most ideal process, simultaneous saccharification and fermentation (SSF) is the most appropriate strategy in practice. In this study, one-pot bioethanol production, including cellulase production, saccharification of cellulose, and ethanol production, was investigated for the conversion of biomass to biofuel by co-culture of two different microorganisms such as a hyper cellulase producer, Acremonium cellulolyticus C-1 and an ethanol producer Saccharomyces cerevisiae. Furthermore, the operational conditions of the one-pot process were evaluated for maximizing ethanol concentration from cellulose in a single reactor.
Results:
Ethanol production from cellulose was carried out in one-pot bioethanol production process. A. cellulolyticus C-1 and S. cerevisiae were co-cultured in a single reactor. Cellulase producing-medium supplemented with 2.5 g/l of yeast extract was used for productions of both cellulase and ethanol. Cellulase production was achieved by A. cellulolyticus C-1 using Solka-Floc (SF) as a cellulase-inducing substrate. Subsequently, ethanol was produced with addition of both 10%(v/v) of S. cerevisiae inoculum and SF at the culture time of 60 h. Dissolved oxygen levels were adjusted at higher than 20% during cellulase producing phase and at lower than 10% during ethanol producing phase. Cellulase activity remained 8--12 FPU/ml throughout the one-pot process. When 50--300 g SF/l was used in 500 ml Erlenmeyer flask scale, the ethanol concentration and yield based on initial SF were as 8.7--46.3 g/l and 0.15--0.18 (g ethanol/g SF), respectively. In 3-l fermentor with 50--300 g SF/l, the ethanol concentration and yield were 9.5--35.1 g/l with their yields of 0.12--0.19 (g/g) respectively, demonstrating that the one-pot bioethanol production is a reproducible process in a scale-up bioconversion of cellulose to ethanol.
Conclusion:
A. cellulolyticus cells produce cellulase using SF. Subsequently, the produced cellulase saccharifies the SF, and then liberated reducing sugars are converted to ethanol by S. cerevisiae. These reactions were carried out in the one-pot process with two different microorganisms in a single reactor, which does require neither an addition of extraneous cellulase nor any pretreatment of cellulose. Collectively, the one-pot bioethanol production process with two different microorganisms could be an alternative strategy for a practical bioethanol production using biomass.Source:
http://www.biotechnologyforbiofuels.com/rss/

Hyperthermophilic endoglucanase for in planta lignocellulose conversion

Background:
The enzymatic conversion of lignocellulosic plant biomass into fermentable sugars is a crucial step in the sustainable and environmentally friendly production of biofuels. However, a major drawback of enzymes from mesophilic sources is their suboptimal activity under established pretreatment conditions, e.g. high temperatures, extreme pH values and high salt concentrations. Enzymes from extremophiles are better adapted to these conditions and could be produced by heterologous expression in microbes, or even directly in the plant biomass.
Results:
Here we show that a cellulase gene (sso1354) isolated from the hyperthermophilic archaeon Sulfolobus solfataricus can be expressed in plants, and that the recombinant enzyme is biologically active and exhibits the same properties as the wild type form. Since the enzyme is inactive under normal plant growth conditions, this potentially allows its expression in plants without negative effects on growth and development, and subsequent heat-inducible activation. Furthermore we demonstrate that the recombinant enzyme acts in high concentrations of ionic liquids and can therefore degrade alpha-cellulose or even complex cell wall preparations under those pretreatment conditions.
Conclusion:
The hyperthermophilic endoglucanase SSO1354 with its unique features is an excellent tool for advanced biomass conversion. Here we demonstrate its expression in planta and the possibility for post harvest activation. Moreover the enzyme is suitable for combined pretreatment and hydrolysis applications.Source:
http://www.biotechnologyforbiofuels.com/rss/

Merger and Acquisition Activity Within the Biotech Industry Soars to a Four-Year High

NEW YORK, NY--(Marketwire -08/30/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation, such as the FAST and TREAT acts, have helped boost investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) is up over 30 percent in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Alexza Pharmaceuticals, Inc. (ALXA) and Discovery Laboratories, Inc. (DSCO).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/ALXA

http://www.FiveStarEquities.com/DSCO

The FAST and TREAT acts introduced in 2012 have helped accelerate the development, review and approval process of medicines/personalized therapies for patients suffering from serious and life-threatening diseases. According to recent data from Thomson Reuters, biotech mergers & acquisitions activity is currently at a four-year high as large pharmaceuticals are facing major patent cliffs. So far in 2012 the volume of biotech M&A has exceeded $25 billion, compared to roughly 10 billion in the same period of 2011.

"Their patents have expired, and as a result they have holes in their revenue line they are trying to fill," said Scott Lindsay, global head of mergers and acquisitions at Credit Suisse. "The other part is just shoring up the pipeline they have. So even if they don't have a major patent problem, they're all looking for growth."

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus -- to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Shares of the company surged earlier this week after analysts at Stifel Nicolaus initiated coverage and set a "buy" rating for the company.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Go here to see the original:
Merger and Acquisition Activity Within the Biotech Industry Soars to a Four-Year High

Biotech Firm Matrix Genetics Receives Investment From Avista Development

SEATTLE, WA--(Marketwire -08/29/12)- Matrix Genetics ("Matrix"), a biotechnology company focused on producing renewable fuels and specialty chemicals derived from cyanobacteria (blue-green algae) announced today that Spokane, Wash. based Avista Development, Inc. has invested in the company. Avista Development is the venture arm of Avista Corp. (AVA), an energy company involved in the production, transmission and distribution of energy as well as other energy-related businesses. The investment provides Matrix with working capital needed to complete its spinout from Seattle-based Targeted Growth, an agricultural biotechnology company where the foundation of Matrix's technology was developed.

"Avista's investment is the springboard for Matrix to become an independent company with the resources to further develop our technologies that are creating a pathway to low-carbon, sustainable and renewable fuels and chemicals," said Margaret McCormick, CEO of Matrix Genetics. "Their support will enable us to add staff, expand our labs, and continue the great tradition of bioscience companies in the state of Washington."

Matrix is developing technologies to leverage the potential of cyanobacteria as a feedstock for the production of a rich diversity of valuable carbon-based chemicals. Cyanobacteria are the most abundant, diverse and robust micro-algae on Earth, using only the energy from sunlight to convert atmospheric carbon dioxide directly into fuels and other biological chemicals. They are also relatively simple, single cell organisms; the genome (the cell's DNA) has already been mapped for several cyanobacteria species; and there is a robust set of "tools" available to modify them.

Matrix has used these tools and the immense power of biotechnology to create new and proprietary strains of cyanobacteria that can produce oil in significant quantities and in a range of specifications. Second and third generation organisms are being developed that not only surpass these oil yields, but also contain additional new traits that enhance their production characteristics and make them suitable for a range of end products including fuels, chemicals and other products.

"Avista has a long history of fostering innovation within the energy sector," said Roger Woodworth, Vice President and Chief Strategy Officer at Avista Corp. "We appreciate the need to find alternatives to petroleum for a sustainable future, and we are excited by the progress and the promise of Matrix's approach."

As the company completes its spinout, Matrix is now focused on further developing its technology to: produce lipids (oils) for fuels and other products; develop production strains that are suitable for different growing environments, resistant to predators and harmless to the environment around them; create strains that continually produce and secrete oils, removing the need for costly harvesting; and increase the cultivation capacity to provide samples for testing with commercialization partners and prospects.

The announcement will be made today at a special event at Matrix Genetics' current lab facilities as part of the "Summer of Algae II," a national campaign sponsored by the Algae Biomass Organization, the trade association for the U.S. algae industry, which features similar open house-style events across the country.

About Matrix GeneticsMatrix Genetics, LLC ("Matrix"), located in Seattle, Wash., is a biotechnology company focused on producing renewable fuel and specialty chemicals derived from cyanobacteria (blue-green algae). The company's state-of-the-art, metabolic engineering and systems biology platform is the most cost-efficient method to customize organisms with a range of traits for these industries. More information is available at http://www.matrixgenetics.com.

Go here to read the rest:
Biotech Firm Matrix Genetics Receives Investment From Avista Development

Biotechnology Has Potential To Be Medium For Sabah's Economic Growth – Musa

You are here : Bernama News

August 30, 2012 15:58 PM

Biotechnology Has Potential To Be Medium For Sabah's Economic Growth - Musa

KOTA KINABALU, Aug 30 (Bernama) -- Biotechnology has the potential to become the "medium" for economic growth and generate new wealth for the state as well as increase the rakyat's income, says Sabah Chief Minister Datuk Seri Musa Aman.

In this regard, he said the state government, through its "Halatuju" development agenda, has outlined the needs for the benefits of science and technology, especially biotechnology for development.

Towards this end, several initiatives have taken off to facilitate the rakyat's participation in biotechnology focusing on knowledge, he said in his speech at a briefing on Bioeconomy in Sabah Development Corridor (SDC), here today.

Also present was Minister of Science, Technology and Innovation Datuk Seri Dr Maximus Ongkili.

Musa, who is also state finance minister, said the initiatives include implementing various key projects such as Sabah Agro-Industrial Precinct (SAIP), Palm Oil Industrial Cluster (POIC) and Keningau Integrated Livestock Farming Centre.

-- BERNAMA

We provide (subscription-based) news coverage in our Newswire service.

Original post:
Biotechnology Has Potential To Be Medium For Sabah's Economic Growth - Musa

Press Conference: Companies to Display Visible Progress in Meeting Advanced Biofuels Goals

Biotechnology Industry Organization (BIO):

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO India International Conference September 12 13, 2012 Mumbai, India

Livestock Biotech Summit September 19 21, 2012 Kansas City, MO

BIO Investor Forum October 9 10, 2012 San Francisco, CA

Pacific Rim Summit on Industrial Biotechnology and Bioenergy October 10 12, 2012 Vancouver, Canada

The BIO Convention in China October 24 25, 2012 Shanghai, China

The rest is here:
Press Conference: Companies to Display Visible Progress in Meeting Advanced Biofuels Goals

Small cap round-up: Angel Biotechnology, Glanbia, MBL Group

LONDON (ShareCast) - Angel Biotechnology (Berlin: A3G.BE - news) has signed an agreement with arGentis Pharmaceuticals that could see it manufacture the firm's ARG201 drug, a treatment for the life-threatening autoimmune disease, systemic sclerosis. Angel's stock rose 6.6% in morning trading.

Glanbia (Irish: GL9.IR - news) , a nutritional solutions and cheese maker, has announced plans to enter a joint venture to incorporate the business and assets of Dairy Ingredients Ireland. The business is the largest dairy ingredients processor in Ireland (Xetra: A0Q8L3 - news) , assembling a milk pool of 1.6bn litres and processing it into around 180,000 tonnes of ingredients, largely for export. The group also reported first half results on Wednesday showing pre-tax profits up 24% on the prior year. Glanbia's shares were up 4% at 11:28.

MBL Group (Berlin: BWYA.BE - news) , an audio and visual entertainment distributor, appears to be clawing its way back to health after losing its most important customer, Morrisons, last year. In its full year results to the end of March, revenues dropped massively, from 195.3m to 28.1m. Revenue from continuing operations dropped from 20m to 17.7 while the loss before tax came in at 2.1m (from discontinued operations this figure was 8.8m). Group loss per share was 40.8p. Nevertheless, MBL is free from debt and has cash balances of 4.0m and a headcount down 75%. This was enough to boost the stock 8% in morning trading.

BS

Read the original:
Small cap round-up: Angel Biotechnology, Glanbia, MBL Group

Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 11:30 a.m. EDT on Wednesday, September 5, at the Stifel Nicolaus 2012 Healthcare Conference in Boston.

A live webcast will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Excerpt from:
Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference

Liquidia Technologies Appoints Dr. Benjamin Yerxa as Chief Scientific Officer

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--

Liquidia Technologies, a privately held biotechnology company developing particle-based vaccines and therapeutics, today announced it has named Benjamin Yerxa, Ph.D. as the companys Chief Scientific Officer. Dr. Yerxa will be responsible for research and development and the overall scientific direction of the company, including a focus on scientific collaborations.

Dr. Yerxa joins Liquidia from Clearside Biomedical, an early stage ophthalmic startup, where he recently assisted the company in securing a Series A financing. Prior to Clearside, Dr. Yerxa was the Executive Vice President and Chief, Research & Development of Inspire Pharmaceuticals, a top ranked publicly traded biotech company recently acquired by Merck & Co., Inc. During his time at Inspire, Dr. Yerxa helped the company build and commercialize a portfolio of innovative new products and provided critical support through multiple rounds of financing, including the companys initial public offering (IPO).

We are very pleased to welcome Ben to the Liquidia team and strongly believe his entrepreneurial spirit and scientific expertise and vision will play an important role in helping us realize the full potential of our PRINT technology, said Neal Fowler, Chief Executive Officer at Liquidia. Bens scientific and corporate accomplishments exemplify Liquidias passion to bring novel products to market that have the potential to transform patients lives.

Throughout his 20-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs) and drug approvals. His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular and HIV. Dr. Yerxa has more than 50 U.S. patents to his name, led a variety of licensing deals including technology transfers and manufacturing agreements and has built several R&D and corporate functions from inception.

Dr. Yerxa has been the recipient of several awards including the Southeastern Region American Chemical Society Industrial Innovation Award and the Triangle Business Journal's "40 under 40" award, recognizing his contributions in business and leadership. Dr. Yerxa serves on the Board of Directors of the North Carolina Biotechnology Center and Sharefish.

ABOUT LIQUIDIA TECHNOLOGIES

Liquidia Technologies is a privately held biotechnology company located in Research Triangle Park, North Carolina. Liquidia was founded in 2004 on the discoveries of Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill, and continues to maintain a powerful collaboration with UNC that enhances the company's ability to develop new PRINT particle based applications. By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition using the PRINT platform, the companys proprietary particle engineering and manufacturing technology. In addition to the development of its own products, Liquidia licenses its cGMP capable PRINT technology to support proprietary programs advanced by collaborators. For more information, please go to http://www.liquidia.com.

View original post here:
Liquidia Technologies Appoints Dr. Benjamin Yerxa as Chief Scientific Officer

Research and Markets: Biotechnology Biotech Finances

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/w886vm/biotechnology_biot) has announced the addition of the "Biotechnology Biotech Finances" subscription to their offering.

The premier European weekly newsletter dedicated to all the financial aspects Biotechnology Biotech Finances has more than 22,000 weekly readers worldwide who use it as their invaluable first point of reference because it:

- Provides up-to-date, pertinent information delivered by experts, investigators and journalists who talk directly to the people who matter;

- Offers efficient networking with professionals through our search engine;

- Helps identify and target potential investors and partners;

- Facilitates exclusive business opportunities, collaboration offers, recruitment, finding investors, acquiring licensing rights, finding equipment and premises, all of which is reported directly by industry leaders in the interviews featured in the newsletter.

Why is Biotech Finances different?

Biotech Finances does not recycle news stories that have already been published elsewhere. A team of specialists actually talk to key players in the field, such as CEOs of leading companies, politicians and regulators. As a result, you'll find news in Biotech Finances that you won't find elsewhere.

In addition, Biotech Finances' tables of financial transactions in the biotechnology field provide early notification of key M&A activity in the sector. Ultimately, Biotech Finances provides the information your business needs to succeed in the dynamic field of biotechnology.

Here is the original post:
Research and Markets: Biotechnology Biotech Finances

Biotech Industry Merger and Acquisition Activity at a Four-Year High

NEW YORK, NY--(Marketwire -08/27/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation, such as the FAST and TREAT acts, have helped boost investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) is up over 30 percent in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Complete Genomics, Inc. (GNOM) and Savient Pharmaceuticals, Inc. (SVNT).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/GNOM

http://www.FiveStarEquities.com/SVNT

The FAST and TREAT acts introduced in 2012 have helped accelerate the development, review and approval process of medicines/personalized therapies for patients suffering from serious and life-threatening diseases. According to recent data from Thomas Reuters, biotech mergers & acquisitions activity is currently at a four-year high as large pharmaceuticals are facing major patent cliffs. So far in 2012 the volume of biotech M&A has exceeded $25 billion, compared to roughly 10 billion in the same period of 2011.

"Their patents have expired, and as a result they have holes in their revenue line they are trying to fill," said Scott Lindsay, global head of mergers and acquisitions at Credit Suisse. "The other part is just shoring up the pipeline they have. So even if they don't have a major patent problem, they're all looking for growth."

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

As the world's first company dedicated to large-scale whole human genome sequencing and bioinformatics analysis provided as a service, Complete Genomics frees researchers from purchasing and operating sequencing instruments and computing infrastructures so they can focus on making biological discoveries. For the second quarter of 2012 the company reported revenue of $8.7 million, compared to $5.9 million in the second quarter of 2011.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. The company recently reported net sales for KRYSTEXXA were $4.0 million for the second quarter of 2012, a 30% increase over the first quarter of 2012.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Go here to see the original:
Biotech Industry Merger and Acquisition Activity at a Four-Year High

Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company's Long-Acting IL-11 Analog to …

BOULDER, Colo., Aug. 28, 2012 /PRNewswire/ --Bolder BioTechnology, Inc. announced today publication of preclinical research demonstrating utility of interleukin-11 (IL-11) and the company's long-acting IL-11 analog to prevent kidney damage from ischemia reperfusion injury in mice. This work may lead to new therapeutic approaches to prevent acute kidney injury and ischemia reperfusion injury to multiple organ types.

The studies were performed in the laboratory of H. Thomas Lee, M.D., Ph.D., Professor and Director of Transplantation Anesthesiology, Department of Anesthesiology, Columbia University, New York, and published as an Advance Online Publication in the American Journal of Physiology Renal Physiology (http://ajprenal.physiology.org; published ahead of print August 1, 2012, doi:10.1152/ajprenal.00220.2012).

George (Joe) Cox, Ph.D., Company President stated "IL-11 is a multifunctional protein that is used clinically to treat thrombocytopenia (low platelet counts) in cancer patients receiving chemotherapy. Dr. Lee's experiments show for the first time that IL-11 also can prevent kidney damage that results when blood flow to the kidneys is temporarily blocked and then restarted (ischemia-reperfusion), such as occurs during many types of major surgeries. Restoring blood flow to the ischemic kidney initiates an inflammatory response that damages the healthy kidney and can lead to acute kidney injury and renal failure. Renal ischemia-reperfusion injury is a major clinical problem that is associated with a high incidence of permanent kidney damage and high mortality in certain patient populations. There are no effective therapies for reducing the incidence of surgery-associated acute kidney injury. Dr. Lee's studies showed that administration of IL-11 or our biosuperior, long-acting IL-11 analog prior to, or shortly after renal ischemia-reperfusion preserved kidney function and significantly reduced the amount of kidney cell necrosis, cell death and inflammation compared to a placebo. Dr. Lee's studies also elucidated the intracellular signaling pathways triggered by IL-11 that are responsible for protecting the kidney from ischemia-reperfusion injury.

This research was supported by grants from the National Institutes of Health to Dr. H. Thomas Lee and to Bolder Biotechnology, Inc.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at http://www.bolderbio.com.

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

More:
Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company's Long-Acting IL-11 Analog to ...

Sugarcane bagasse pretreatment using three imidazolium-based ionic liquids; mass balances and enzyme kinetics

Background:
Effective pretreatment is key to achieving high enzymatic saccharification efficiency in processing lignocellulosic biomass to fermentable sugars, biofuels and value-added products. Ionic liquids (ILs), still relatively new class of solvents, are attractive for biomass pretreatment because some demonstrate the rare ability to dissolve all components of lignocellulosic biomass including highly ordered (crystalline) cellulose. In the present study, three ILs, 1-butyl-3-methylimidazolium chloride ([C4mim]Cl), 1-ethyl-3-methylimidazolium chloride ([C2mim]Cl), 1-ethyl-3-methylimidazolium acetate ([C2mim]OAc) are used to dissolve/pretreat and fractionate sugarcane bagasse. In these IL-based pretreatments the biomass is completely or partially dissolved in ILs at temperatures greater than 130[DEGREE SIGN]C and then precipitated by the addition of an antisolvent to the IL biomass mixture. For the first time mass balances of IL-based pretreatments are reported. Such mass balances, along with kinetics data, can be used in process modelling and design.
Results:
Lignin removals of 10% mass of lignin in bagasse with [C4mim]Cl, 50% mass with [C2mim]Cl and 60% mass with [C2mim]OAc, are achieved by limiting the amount of water added as antisolvent to 0.5 water:IL mass ratio thus minimising lignin precipitation. Enzyme saccharification (24 h, 15FPU) yields (% cellulose mass in starting bagasse) from the recovered solids rank as: [C2mim]OAc(83%)>>[C2mim]Cl(53%) = [C4mim]Cl(53%). Composition of [C2mim]OAc-treated solids such as low lignin, low acetyl group content and preservation of arabinosyl groups are characteristic of aqueous alkali pretreatments while those of chloride IL-treated solids resemble aqueous acid pretreatments. All ILs are fully recovered after use (100% mass as determined by ion chromatography).
Conclusions:
In all three ILs regulated addition of water as an antisolvent effected a polysaccharide enriched precipitate since some of the lignin remained dissolved in the aqueous IL solution. Of the three IL studied [C2mim]OAc gave the best saccharification yield, material recovery and delignification. The effects of [C2mim]OAc pretreatment resemble those of aqueous alkali pretreatments while those of [C2mim]Cl and [C4mim]Cl resemble aqueous acid pretreatments. The use of imidazolium IL solvents with shorter alkyl chains results in accelerated dissolution, pretreatment and degradation.Source:
http://www.biotechnologyforbiofuels.com/rss/

BIO Thanks Romney, Ryan for Supporting Energy Security and Standing Firm on the Renewable Fuel Standard

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) today thanked Gov. Mitt Romney for his stated intention to support increased market penetration and competition among energy sources by maintaining the RFS in The Romney Plan For A Stronger Middle Class: ENERGY INDEPENDENCE, released yesterday.

BIO President and CEO Jim Greenwood said, The Renewable Fuel Standard is the bedrock policy supporting the emergence of advanced biofuels. The United States is at a critical juncture in the development of advanced biofuels, which are poised to make a real contribution to energy independence and security. Companies across the United States have made substantial long-term investments in building new biorefineries. The first commercial gallons of cellulosic biofuels were produced this year and the first large-scale biorefineries are set to begin production soon, adding to those gallons. Additional large-scale biorefineries are under construction, with production ready to begin within the next few years.

Stable support for the Renewable Fuel Standard at the federal level provides assurance to these companies that their investments will come to fruition. Innovative biofuels have already brought competition among energy sources to the marketplace and lowered prices for consumers. Further, construction and operation of biorefineries will continue to generate new employment opportunities.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO India International Conference September 12 13, 2012 Mumbai, India

Livestock Biotech Summit September 19 21, 2012 Kansas City, MO

BIO Investor Forum October 9 10, 2012 San Francisco, CA

Read more here:
BIO Thanks Romney, Ryan for Supporting Energy Security and Standing Firm on the Renewable Fuel Standard

Very high gravity ethanol fermentation by flocculating yeast under redox potential-controlled conditions

Background:
Very high gravity (VHG) fermentation using medium in excess of 250 g/L sugars for more than 15 % (v) ethanol can save energy consumption, not only for ethanol distillation, but also for distillage treatment; however, stuck fermentation with prolonged fermentation time and more sugars unfermented is the biggest challenge. Controlling redox potential (ORP) during VHG fermentation benefits biomass accumulation and improvement of yeast cell viability that is affected by osmotic pressure and ethanol inhibition, enhancing ethanol productivity and yield, the most important techno-economic aspect of fuel ethanol production.
Results:
Batch fermentation was performed under different ORP conditions using the flocculating yeast and media containing glucose of 201 [PLUS-MINUS SIGN] 3.1, 252 [PLUS-MINUS SIGN] 2.9 and 298 [PLUS-MINUS SIGN] 3.8 g/L. Compared with ethanol fermentation by non-flocculating yeast, different ORP profiles were observed with the flocculating yeast due to the morphological change associated with the flocculation of yeast cells. When ORP was controlled at [MINUS SIGN]100 mV, ethanol fermentation with the high gravity (HG) media containing glucose of 201 [PLUS-MINUS SIGN] 3.1 and 252 [PLUS-MINUS SIGN] 2.9 g/L was completed at 32 and 56 h, respectively, producing 93.0 [PLUS-MINUS SIGN] 1.3 and 120.0 [PLUS-MINUS SIGN] 1.8 g/L ethanol, correspondingly. In contrast, there were 24.0 [PLUS-MINUS SIGN] 0.4 and 17.0 [PLUS-MINUS SIGN] 0.3 g/L glucose remained unfermented without ORP control. As high as 131.0 [PLUS-MINUS SIGN] 1.8 g/L ethanol was produced at 72 h when ORP was controlled at [MINUS SIGN]150 mV for the VHG fermentation with medium containing 298 [PLUS-MINUS SIGN] 3.8 g/L glucose, since yeast cell viability was improved more significantly.
Conclusions:
No lag phase was observed during ethanol fermentation with the flocculating yeast, and the implementation of ORP control improved ethanol productivity and yield. When ORP was controlled at [MINUS SIGN]150 mV, more reducing power was available for yeast cells to survive, which in turn improved their viability and VHG ethanol fermentation performance. On the other hand, controlling ORP at [MINUS SIGN]100 mV stimulated yeast growth and enhanced ethanol production under the HG conditions. Moreover, the ORP profile detected during ethanol fermentation with the flocculating yeast was less fluctuated, indicating that yeast flocculation could attenuate the ORP fluctuation observed during ethanol fermentation with non-flocculating yeast.Source:
http://www.biotechnologyforbiofuels.com/rss/